Fig 7.

Synthesis of truncated HSV1 pUL36 proteins. Vero cells were mock treated (mock) or infected at an MOI of 10 PFU/cell with HSV1(17⁺)blueLox (wt) or with mutant HSV1(17⁺)blueLox-UL36codon2211stop, -UL36codon2430stop, -UL36codon2894stop, or -UL36codon2998stop or HSV1(17⁺)blueLox-ΔUL36 (Δ), transcomplemented with pUL36 by amplification on Vero-HS30 cells, and harvested at 10 h p.i. The proteins were separated by linear 5 to 15% gradient SDS-PAGE, transferred to nitrocellulose membranes, and probed with antibodies directed against pUL36 aa 109 to 333 (A; pAb VP1-2 N), pUL36 aa 1408 to 2112 (B; middle, pAb 146), and pUL36 aa 3048 to 3057 (C; Cterm, pAb R29) and, as loading controls, antibodies against VP16 (A to C; MAb LP1), gB (B; pAb R68), VP19c (B; pAb NC2), VP22 (B; pAb AGV30), or actin (A to C; MAb 1501).